News

Fralin Biomedical Research Institute officially opens $90 million addition

State and local officials gathered for the grand opening of the newest building at the Fralin Biomedical Research Institute in Roanoke.

The COVID-19 pandemic delayed the ribbon-cutting ceremony for the 139,000-square-foot addition, which opened to researchers and staff last summer. The building, located at 4 Riverside Circle on the Virginia Tech Carilion Health Sciences campus, will accommodate at least 400 more researchers, students and staff.

“Today was worth the wait,” Carilion CEO Nancy Agee said. “We’re putting Roanoke on the map for biosciences.”

The $90-million building houses advanced MRI and CT imaging machines, 3D printers, and microscopes that can see down to the nanometer. One researcher said the microscope he uses for his research costs as much as two Lamborghinis — about $750,000.

Researchers are using this technology to study brain formation, cancer cells, heart disease and memory.

The facility is also home to Virginia Tech’s molecular diagnostics lab, which has processed more than 160,000 COVID-19 tests since April 2020. The facility also holds the Virginia Tech Animal Cancer Care and Research Center to provide medical, surgical and radiation oncology treatments to cats and dogs.

Rachana Somaiya, a graduate student at the institute, said she has been studying how circuits in the brain form and how that could connect to solutions for brain-centered diseases. She said her parents, who live in India, never got the opportunity to attend college and she is grateful to be able to study at the institute and in its newest facility.

“I feel thankful to be a scientist studying the stunning complexity of the brain,” Somaiya said.

“It’s because this institute gave me a chance for quality education and more importantly, a welcoming environment to conduct extraordinary scientific research.”

Learn more here.

Recent News

07/15/2025

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the

07/15/2025

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO. “We are excited to welcome Dave to our leadership team,” said McCoy. “His deep

07/14/2025

Nanochon Announces Health Canada Approval for First in Human Investigation

Nanochon, a Washington, DC and Baltimore, MD-based orthopedic device biotech company developing an implant for treating articular cartilage defects in the knee, is thrilled to announce that it was granted Health Canada approval for their first in human clinical trial. The trial will be led by Principal Investigator, Dr. Fathi Abuzgaya, who will collaborate with